A study evaluating patients diagnosed with thyroid cancer who refused a clinical intervention for fear of being overdiagnosed has reported that the individuals feel isolated and anxious.
A study evaluating patients diagnosed with thyroid cancer who refused a clinical intervention for fear of being overdiagnosed has reported that the individuals feel isolated and anxious. Additionally, they are at a risk of disengaging from healthcare.
Cancer overdiagnosis has been a global concern among health services researchers. Improved diagnostic tools, increased patient awareness, and a greater emphasis on medical surveillance have together contributed to this phenomenon. Nearly 60% of thyroid cancers in developed nations were diagnosed because the population had access to better tools, which raises questions around increased regulation and consideration for watchful waiting, rather than treatment.
However, according to the current study published in JAMA Otolaryngology-Head and Neck Surgery, interviews with individuals who self-identified as being overdiagnosed and refused treatment identified feelings of anxiety and isolation. The study authors interviewed 22 individuals (range, 21-75 years), primarily female, who had been diagnosed with thyroid cancer—18 of them had refused an intervention and had been living with the decision for a median time of 39 months (range, 1-88 months).
Twelve of the 18 participants reported significant anxiety regarding their cancer progression, but explained that their decision was based on:
Twelve of them also reported absence of support from medical professionals, friends, and social media groups, including suggestions that they had made the wrong decision. Only 3 of the 18 said they had successfully connected with others about their experience, while 15 individuals had kept their diagnosis a secret. Five participants had disengaged themselves from medical surveillance, which is the recommended alternative to an active intervention for patients diagnosed with thyroid cancer.
The authors express concern that individuals diagnosed with thyroid cancer who choose nonintervention are at risk of disengaging from healthcare. They recommend lending social and health system support and education for this population to keep them engaged with their surveillance and ultimately, to promote quality healthcare.
“Culturally we are conditioned to think that if you’re diagnosed with cancer, you have to do everything you can to rid your body of that cancer. Changing attitudes toward non-intervention is likely to require a change in our larger social and media culture,” senior author Louise Davies, MD, MS, associate professor at The Dartmouth Institute and Chief of Otolaryngology at Veterans Administration in White River Junction, Vermont, said in a statement.
Reference
Davies L, Hendrickson CD, Hanson GS. Experience of US patients who self-identify as having an overdiagnosed thyroid cancer: a qualitative analysis [published online March 9, 2017]. JAMA Otolaryngol Head Neck Surg. doi: 10.1001/jamaoto.2016.4749.
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Government agencies have created an online portal for the public to report potential anticompetitive practices in health care; there are changes coming to the “boxed warning” section for chimeric antigen receptor T-cell therapies (CAR T) to highlight T-cell blood cancer risk; questions about the safety of obesity medications during pregnancy have arisen in women on them who previously struggled with fertility issues.
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Gene, Light Therapy Combo Shows Promise Against Prostate Cancer Cells in Proof-of-Concept Study
April 18th 2024In their preclinical model, the researchers found efficacy both in vitro and in vivo by using CRISPR-Cas9 to mimic porphyria and combining the technology with light therapy.
Read More
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More